Status: Not yet recruiting
This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria
The goal of this Phase 2b study is to examine the safety and efficacy of the combination of SJ733, an investigational agent, and tafenoquine for the radical cure of uncomplicated P. vivax malaria monoinfection in adult participants and determine the contributions of SJ733 to the effect. SJ733 will be administered in a 1-, 2-, or 3-day treatment schedule in combination with a single dose of tafenoquine.
Participants needed: 104
Trial details
Phase: Phase 2Age: 18-76Biological sex: AllType: InterventionalSponsor: R. Kiplin GuyUpdated: May 28, 2026Locations: 1
Eligibility criteria
Body weight between 45 kg and 90 kg inclusive. [+9]
Signs and symptoms of severe/complicated malaria according to the World Health O... [+26]